|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MPST |
Gene summary for MPST |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MPST | Gene ID | 4357 |
| Gene name | mercaptopyruvate sulfurtransferase | |
| Gene Alias | MST | |
| Cytomap | 22q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000096 | UniProtAcc | A0A140VJX3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4357 | MPST | P27T-E | Human | Esophagus | ESCC | 1.64e-54 | 1.24e+00 | 0.1055 |
| 4357 | MPST | P28T-E | Human | Esophagus | ESCC | 2.10e-26 | 6.84e-01 | 0.1149 |
| 4357 | MPST | P30T-E | Human | Esophagus | ESCC | 3.06e-43 | 1.87e+00 | 0.137 |
| 4357 | MPST | P31T-E | Human | Esophagus | ESCC | 5.05e-65 | 1.29e+00 | 0.1251 |
| 4357 | MPST | P32T-E | Human | Esophagus | ESCC | 1.09e-15 | 5.43e-01 | 0.1666 |
| 4357 | MPST | P36T-E | Human | Esophagus | ESCC | 2.91e-12 | 5.65e-01 | 0.1187 |
| 4357 | MPST | P37T-E | Human | Esophagus | ESCC | 9.91e-23 | 5.11e-01 | 0.1371 |
| 4357 | MPST | P38T-E | Human | Esophagus | ESCC | 1.42e-10 | 7.36e-01 | 0.127 |
| 4357 | MPST | P39T-E | Human | Esophagus | ESCC | 8.71e-17 | 4.79e-01 | 0.0894 |
| 4357 | MPST | P40T-E | Human | Esophagus | ESCC | 4.95e-38 | 1.34e+00 | 0.109 |
| 4357 | MPST | P42T-E | Human | Esophagus | ESCC | 2.66e-33 | 1.07e+00 | 0.1175 |
| 4357 | MPST | P44T-E | Human | Esophagus | ESCC | 5.15e-13 | 4.13e-01 | 0.1096 |
| 4357 | MPST | P47T-E | Human | Esophagus | ESCC | 6.88e-16 | 4.15e-01 | 0.1067 |
| 4357 | MPST | P48T-E | Human | Esophagus | ESCC | 1.85e-32 | 7.84e-01 | 0.0959 |
| 4357 | MPST | P49T-E | Human | Esophagus | ESCC | 2.85e-15 | 1.41e+00 | 0.1768 |
| 4357 | MPST | P52T-E | Human | Esophagus | ESCC | 5.39e-39 | 9.60e-01 | 0.1555 |
| 4357 | MPST | P54T-E | Human | Esophagus | ESCC | 1.01e-12 | 3.60e-01 | 0.0975 |
| 4357 | MPST | P56T-E | Human | Esophagus | ESCC | 2.40e-11 | 1.26e+00 | 0.1613 |
| 4357 | MPST | P57T-E | Human | Esophagus | ESCC | 5.87e-27 | 6.70e-01 | 0.0926 |
| 4357 | MPST | P61T-E | Human | Esophagus | ESCC | 3.96e-48 | 1.34e+00 | 0.099 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0044282 | Colorectum | AD | small molecule catabolic process | 118/3918 | 376/18723 | 1.05e-06 | 3.55e-05 | 118 |
| GO:0009636 | Colorectum | AD | response to toxic substance | 88/3918 | 262/18723 | 1.12e-06 | 3.72e-05 | 88 |
| GO:0061008 | Colorectum | AD | hepaticobiliary system development | 55/3918 | 150/18723 | 6.34e-06 | 1.59e-04 | 55 |
| GO:0001889 | Colorectum | AD | liver development | 54/3918 | 147/18723 | 7.20e-06 | 1.77e-04 | 54 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0016054 | Colorectum | AD | organic acid catabolic process | 73/3918 | 240/18723 | 3.20e-04 | 3.81e-03 | 73 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:00487321 | Colorectum | SER | gland development | 112/2897 | 436/18723 | 1.75e-08 | 1.28e-06 | 112 |
| GO:00096361 | Colorectum | SER | response to toxic substance | 71/2897 | 262/18723 | 8.63e-07 | 4.07e-05 | 71 |
| GO:00610081 | Colorectum | SER | hepaticobiliary system development | 45/2897 | 150/18723 | 4.98e-06 | 1.85e-04 | 45 |
| GO:00018891 | Colorectum | SER | liver development | 44/2897 | 147/18723 | 6.73e-06 | 2.35e-04 | 44 |
| GO:00442821 | Colorectum | SER | small molecule catabolic process | 87/2897 | 376/18723 | 5.31e-05 | 1.27e-03 | 87 |
| GO:00442701 | Colorectum | SER | cellular nitrogen compound catabolic process | 99/2897 | 451/18723 | 1.46e-04 | 2.86e-03 | 99 |
| GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
| GO:00160541 | Colorectum | SER | organic acid catabolic process | 53/2897 | 240/18723 | 4.04e-03 | 3.30e-02 | 53 |
| GO:00065201 | Colorectum | SER | cellular amino acid metabolic process | 61/2897 | 284/18723 | 4.20e-03 | 3.41e-02 | 61 |
| GO:00487322 | Colorectum | MSS | gland development | 143/3467 | 436/18723 | 3.85e-13 | 8.01e-11 | 143 |
| GO:00442702 | Colorectum | MSS | cellular nitrogen compound catabolic process | 141/3467 | 451/18723 | 2.95e-11 | 3.83e-09 | 141 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00920 | Colorectum | AD | Sulfur metabolism | 8/2092 | 10/8465 | 3.78e-04 | 2.82e-03 | 1.80e-03 | 8 |
| hsa009201 | Colorectum | AD | Sulfur metabolism | 8/2092 | 10/8465 | 3.78e-04 | 2.82e-03 | 1.80e-03 | 8 |
| hsa009202 | Colorectum | SER | Sulfur metabolism | 8/1580 | 10/8465 | 4.56e-05 | 5.22e-04 | 3.79e-04 | 8 |
| hsa009203 | Colorectum | SER | Sulfur metabolism | 8/1580 | 10/8465 | 4.56e-05 | 5.22e-04 | 3.79e-04 | 8 |
| hsa009204 | Colorectum | MSS | Sulfur metabolism | 6/1875 | 10/8465 | 1.07e-02 | 3.74e-02 | 2.29e-02 | 6 |
| hsa009205 | Colorectum | MSS | Sulfur metabolism | 6/1875 | 10/8465 | 1.07e-02 | 3.74e-02 | 2.29e-02 | 6 |
| hsa009206 | Colorectum | FAP | Sulfur metabolism | 6/1404 | 10/8465 | 2.36e-03 | 1.13e-02 | 6.85e-03 | 6 |
| hsa009207 | Colorectum | FAP | Sulfur metabolism | 6/1404 | 10/8465 | 2.36e-03 | 1.13e-02 | 6.85e-03 | 6 |
| hsa002704 | Endometrium | EEC | Cysteine and methionine metabolism | 15/1237 | 52/8465 | 6.02e-03 | 3.12e-02 | 2.33e-02 | 15 |
| hsa0027011 | Endometrium | EEC | Cysteine and methionine metabolism | 15/1237 | 52/8465 | 6.02e-03 | 3.12e-02 | 2.33e-02 | 15 |
| hsa0092010 | Esophagus | ESCC | Sulfur metabolism | 9/4205 | 10/8465 | 1.01e-02 | 2.38e-02 | 1.22e-02 | 9 |
| hsa0092011 | Esophagus | ESCC | Sulfur metabolism | 9/4205 | 10/8465 | 1.01e-02 | 2.38e-02 | 1.22e-02 | 9 |
| hsa00270 | Liver | Cirrhotic | Cysteine and methionine metabolism | 27/2530 | 52/8465 | 6.98e-04 | 4.15e-03 | 2.56e-03 | 27 |
| hsa002701 | Liver | Cirrhotic | Cysteine and methionine metabolism | 27/2530 | 52/8465 | 6.98e-04 | 4.15e-03 | 2.56e-03 | 27 |
| hsa002702 | Liver | HCC | Cysteine and methionine metabolism | 35/4020 | 52/8465 | 3.03e-03 | 9.94e-03 | 5.53e-03 | 35 |
| hsa002703 | Liver | HCC | Cysteine and methionine metabolism | 35/4020 | 52/8465 | 3.03e-03 | 9.94e-03 | 5.53e-03 | 35 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MPST | SNV | Missense_Mutation | rs377346580 | c.916N>A | p.Glu306Lys | p.E306K | P25325 | protein_coding | deleterious(0.03) | benign(0.097) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MPST | SNV | Missense_Mutation | c.664C>T | p.Pro222Ser | p.P222S | P25325 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPST | SNV | Missense_Mutation | novel | c.587N>A | p.Arg196Gln | p.R196Q | P25325 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MPST | SNV | Missense_Mutation | novel | c.469N>T | p.Arg157Cys | p.R157C | P25325 | protein_coding | deleterious(0.01) | possibly_damaging(0.546) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| MPST | SNV | Missense_Mutation | novel | c.431N>T | p.Ala144Val | p.A144V | P25325 | protein_coding | tolerated(0.08) | benign(0.023) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MPST | SNV | Missense_Mutation | novel | c.949N>T | p.His317Tyr | p.H317Y | P25325 | protein_coding | deleterious_low_confidence(0.01) | benign(0.007) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MPST | SNV | Missense_Mutation | novel | c.389C>T | p.Ala130Val | p.A130V | P25325 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MPST | SNV | Missense_Mutation | novel | c.476N>T | p.Asn159Ile | p.N159I | P25325 | protein_coding | deleterious(0) | benign(0.123) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MPST | SNV | Missense_Mutation | novel | c.632G>A | p.Gly211Asp | p.G211D | P25325 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| MPST | SNV | Missense_Mutation | novel | c.433G>A | p.Val145Met | p.V145M | P25325 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4357 | MPST | ENZYME, DRUGGABLE GENOME | inhibitor | 381744892 | ||
| 4357 | MPST | ENZYME, DRUGGABLE GENOME | THYROXINE | THYROXINE | 10709617 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |